Eating Disorders and Addictive Behaviors: Implications for Human Health

Fernando Fernández-Aranda; Roser Granero; Susana Jiménez-Murcia

doi:10.3390/nu15173718

Eating Disorders and Addictive Behaviors: Implications for Human Health

Nutrients. 2023 Aug 25;15(17):3718. doi: 10.3390/nu15173718.

Authors

Fernando Fernández-Aranda^{1

2

3

4}, Roser Granero^{1

2

5}, Susana Jiménez-Murcia^{1

2

3

4}

Affiliations

¹ CIBER Physiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, 28029 Madrid, Spain.
² Psychoneurobiology of Eating and Addictive Behaviors Group, Neurosciences Programme, Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain.
³ Clinical Psychology Unit, University Hospital of Bellvitge, 08907 Barcelona, Spain.
⁴ Department of Clinical Sciences, School of Medicine and Health Sciences, University of Barcelona, 08907 L'Hospitalet de Llobregat, Spain.
⁵ Department of Psychobiology and Methodology, Autonomous University of Barcelona, 08193 Barcelona, Spain.

Abstract

Eating disorders (EDs) are mental health diseases characterized by dysfunctional eating patterns, including restrictive eating, avoidance of foods, binge eating, and compensative behaviors to avoid weight increases and promote thinness (purging, vomiting, laxative/diuretics misuse, and compulsive exercise) [...].

Publication types

Editorial

MeSH terms

Behavior, Addictive*
Binge-Eating Disorder*
Bulimia*
Diuretics
Feeding and Eating Disorders*
Humans

Substances

Diuretics

Grants and funding

This research was funded by Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and co-funded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. CIBERobn is an initiative of ISCIII. This work was additionally supported by a grant from the Ministerio de Ciencia, Innovación y Universidades (grant RTI2018-101837-B-100), the Delegación del Gobierno para el Plan Nacional sobre Drogas (2019I47 and 2021I031). This study was also funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multimorbidity in Europe). Additional funding was received from AGAUR-Generalitat de Catalunya (2021-SGR-00824). R.G. was supported by the Catalan Institution for Research and Advanced Studies (ICREA-Academia, 2021-Programme).